Keyword: Regeneron Pharmaceuticals
The move gives Sanofi the right to opt-in to two bispecific programs but otherwise leaves each company free to operate independently.
The strong early signs of efficacy led Regeneron to target a 2019 start date for a potentially registrational phase 2 study.
Kronos Bio snagged Regeneron’s business development director, Philip Gutry, to be its chief business officer and manage its pipeline alliances.
Clearside Biomedical has cratered after revealing its top drug failed a phase 3 trial in retinal vein occlusion, a common cause of vision loss.
Ex-Gilead CMO Andrew Cheng to lead Akero; Sanofi trades executives with Bayer in restructuring; and Crescendo names ex-Roche leader as CMO.
A management review at Bayer could result in job cuts and outsourcing the company’s drug-testing services, according to Reuters.
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
Regenxbio's gene therapy for wet age-related macular degeneration (AMD) reduced the need for in-eye injections of anti-VEGF drugs.
The pact combines Regeneron’s antibody expertise with Bluebird’s cell therapy toolkit to expand the list of tumors modified T cells can treat.